Related Experiment Video
Updated: Apr 28, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
Second-generation ALK inhibitors: filling the non "MET" gap
Suresh S Ramalingam1, Fadlo R Khuri2
1Authors' Affiliation: Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia.
Second-generation inhibitors like ceritinib show promise against anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). These drugs overcome resistance mutations, offering new treatment options for ALK-positive NSCLC patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is a distinct subtype of lung cancer.
- Crizotinib, an early ALK inhibitor, faces challenges with acquired resistance mutations.
- Gatekeeper mutations can confer resistance to first-generation ALK inhibitors.
Purpose of the Study:
- To evaluate the efficacy of second-generation ALK inhibitors, such as ceritinib.
- To assess the ability of these inhibitors to overcome resistance mechanisms in ALK-positive NSCLC.
- To highlight new therapeutic avenues for managing advanced ALK-positive NSCLC.
Main Methods:
- Clinical studies evaluating second-generation ALK inhibitors.
- In vitro or in vivo models assessing drug activity against resistant mutations.
- Analysis of patient outcomes in ALK-positive NSCLC.
Main Results:
- Ceritinib and similar agents demonstrate significant anticancer activity.
- These inhibitors effectively target ALK mutations, including gatekeeper mutations.
- Resistance to prior therapies can be overcome by second-generation inhibitors.
Conclusions:
- Second-generation ALK inhibitors represent a significant advancement in treating ALK-positive NSCLC.
- These agents offer improved therapeutic options for patients who have developed resistance to crizotinib.
- The management of ALK-positive NSCLC is enhanced by the availability of these newer drugs.
More Related Videos
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
04:36Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Enzyme Inhibition
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Antihypertensive Drugs: Direct Renin Inhibitors
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Inhibitors of Bacterial Protein Synthesis